Sam Hopkins

Summary

Publications

  1. doi request reprint The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection
    Sam Hopkins
    SCYNEXIS, Inc, Durham, NC, United States
    J Hepatol 57:47-54. 2012
  2. pmc Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection
    Sam Hopkins
    Autoimmune Technologies, LLC, 1010 Common Street, Suite 1705, New Orleans, LA 70112, USA
    Viruses 4:2558-77. 2012
  3. pmc SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
    Sam Hopkins
    SCYNEXIS, Inc, 3501C Tricenter Boulevard, Durham, NC 27713, USA
    Antimicrob Agents Chemother 54:660-72. 2010
  4. pmc The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
    Sam Hopkins
    SCYNEXIS, Inc, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 56:3888-97. 2012

Collaborators

Detail Information

Publications4

  1. doi request reprint The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection
    Sam Hopkins
    SCYNEXIS, Inc, Durham, NC, United States
    J Hepatol 57:47-54. 2012
    ..In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection...
  2. pmc Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection
    Sam Hopkins
    Autoimmune Technologies, LLC, 1010 Common Street, Suite 1705, New Orleans, LA 70112, USA
    Viruses 4:2558-77. 2012
    ....
  3. pmc SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
    Sam Hopkins
    SCYNEXIS, Inc, 3501C Tricenter Boulevard, Durham, NC 27713, USA
    Antimicrob Agents Chemother 54:660-72. 2010
    ..These results suggest that SCY-635 warrants further investigation as a novel therapeutic agent for the treatment of individuals who are chronically infected with HCV...
  4. pmc The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes
    Sam Hopkins
    SCYNEXIS, Inc, Research Triangle Park, North Carolina, USA
    Antimicrob Agents Chemother 56:3888-97. 2012
    ..These specific mutations in NS5A eliminate the dependence of HCV RNA replication on the expression of host CypA...